期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 21, 期 3, 页码 343-359出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14712598.2021.1832462
关键词
Duchenne muscular dystrophy; exon skipping; antisense oligonucleotide; genome editing; therapy; clinical trials; personalized medicine
资金
- Duchenne Parent Project (Netherlands)
- Sarepta Therapeutics
- Charlie's Fund
- Spieren voor Spieren (Netherlands)
- Duchenne UK
- Horizon 2020 (BIND) [847826]
Three AONS have been approved, but the sufficiency of dystrophin levels to slow down disease progression needs further confirmation. Current research is focusing on improving muscle uptake of AONs, as well as exploring gene editing as an alternative method.
Introduction Exon skipping compounds restoring the dystrophin transcript reading frame have received regulatory approval for Duchenne muscular dystrophy (DMD). Recently, focus shifted to developing compounds to skip additional exons, improving delivery to skeletal muscle, and to genome editing, to restore the reading frame on DNA level. Areas covered We outline developments for reading frame restoring approaches, challenges of mutation specificity, and optimizing delivery. Also, we highlight ongoing efforts to better detect exon skipping therapeutic effects in clinical trials. Searches on relevant terms were performed, focusing on recent publications (<3 years). Expert opinion Currently, 3 AONS are approved. Whether dystrophin levels are sufficient to slowdown disease progression needs to be confirmed. Enhancing AON uptake by muscles is currently under investigation. Gene editing is an alternative, but one that involves practical and ethical concerns. Given the field's momentum, we believe the efficiency of frame-restoring approaches will improve.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据